Genodermatoses Stocks List

Recent Signals

Date Stock Signal Type
2021-03-05 INM 50 DMA Resistance Bearish
2021-03-05 INM MACD Bearish Centerline Cross Bearish
2021-03-05 INM 1,2,3 Pullback Bullish Bullish Swing Setup
2021-03-05 INM Stochastic Reached Oversold Weakness
2021-03-05 KROS Stochastic Buy Signal Bullish
2021-03-05 KROS 200 DMA Support Bullish
2021-03-05 KROS Hammer Candlestick Bullish
2021-03-05 KROS Lower Bollinger Band Walk Weakness
2021-03-05 KRYS Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-03-05 KRYS Hammer Candlestick Bullish
2021-03-05 KRYS 50 DMA Support Bullish
2021-03-05 KRYS Lizard Bullish Bullish Day Trade Setup
2021-03-05 OVID Calm After Storm Range Contraction
2021-03-05 RCEL Expansion Pivot Sell Setup Bearish Swing Setup
2021-03-05 RCEL Wide Range Bar Range Expansion
2021-03-05 RCEL Stochastic Reached Oversold Weakness
2021-03-05 TMBR 180 Bullish Setup Bullish Swing Setup
2021-03-05 TMBR 200 DMA Support Bullish
2021-03-05 TMBR 20 DMA Resistance Bearish
2021-03-05 TMBR 1,2,3 Pullback Bullish Bullish Swing Setup
2021-03-05 TMBR Non-ADX 1,2,3,4 Bullish Bullish Swing Setup

Recent News for Genodermatoses Stocks

Date Stock Title
Mar 5 WVE Wave Life Sciences Ltd. 2020 Q4 - Results - Earnings Call Presentation
Mar 5 KROS Keros Therapeutics reports preclinical data from hematology programs
Mar 5 KROS Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference
Mar 4 WVE Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q4 2020 Results - Earnings Call Transcript
Mar 4 WVE Looking Into WAVE Life Sciences's Return On Capital Employed
Mar 4 WVE Wave Life Sciences (WVE) Reports Q4 Loss, Lags Revenue Estimates
Mar 4 WVE WAVE Life Sciences: Q4 Earnings Insights
Mar 4 WVE Wave Life Sciences EPS beats by $0.03, misses on revenue
Mar 4 WVE Wave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Mar 4 WVE Earnings Scheduled For March 4, 2021
Mar 3 INM InMed to Present at Virtual Conferences in March 2021
Mar 3 OVID FUBO, RKT, TRXC and SOS among midday movers
Mar 3 OVID Ovid downgraded to sector perform at RBC as shares surge 34% on Takeda deal
Mar 3 OVID Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy Syndromes
Mar 3 OVID The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study
Mar 3 OVID 5 Top Stock Gainers for Wednesday: Michaels, Alcoa, Ovid Therapeutics
Mar 3 OVID Ovid shares surge 92% after soticlestat deal with Takeda
Mar 3 OVID Takeda buys epilepsy treatment rights from Ovid for up to $856 mln
Mar 3 OVID Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
Mar 2 KROS Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference
Related Industries: Biotechnology Medical Devices

Genodermatoses are inherited genetic skin conditions often grouped into three categories: chromosomal, single gene, and polygenetic.

More about Genodermatoses
Browse All Tags